Filtered By:
Source: Cardiology Journal
Condition: Bleeding
This page shows you your search results in order of date.
Order by Relevance | Date
Total 102 results found since Jan 2013.
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
CONCLUSIONS: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding.PMID:36200548 | DOI:10.5603/CJ.a2022.0091
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Manuel Anguita S ánchez Francisco Mar ín Jaime Masjuan Juan Cos ín-Sales Jos é Manuel Vázquez Rodríguez Vivencio Barrios Gonzalo Bar ón-Esquivias I ñaki Lekuona Alejandro I P érez-Cabeza Rom án Freixa-Pamias Francisco Javier Parra Jimenez Mohame Source Type: research
Should targeted temperature management be used in cardiogenic shock patients? Systematic review and meta-analysis
CONCLUSIONS: The present analysis shows no significant benefit of TTM in patients with CS. Moreover, no statistically significant increase of the incidence of adverse effects was found. However, further randomized studies with higher sample size and greater validity are needed to determine if TTM is worth implementing in CS patients.PMID:36200546 | DOI:10.5603/CJ.a2022.0093
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Adam Nieborek Jerzy R Ladny Milosz J Jaguszewski Andrea Denegri Aleksandra Sikora Szymon Pucylo Aleksandra Gasecka Michal Pruc Ivan Savytsky Lukasz Szarpak Source Type: research
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
CONCLUSIONS: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding.PMID:36200548 | DOI:10.5603/CJ.a2022.0091
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Manuel Anguita S ánchez Francisco Mar ín Jaime Masjuan Juan Cos ín-Sales Jos é Manuel Vázquez Rodríguez Vivencio Barrios Gonzalo Bar ón-Esquivias I ñaki Lekuona Alejandro I P érez-Cabeza Rom án Freixa-Pamias Francisco Javier Parra Jimenez Mohame Source Type: research
Should targeted temperature management be used in cardiogenic shock patients? Systematic review and meta-analysis
CONCLUSIONS: The present analysis shows no significant benefit of TTM in patients with CS. Moreover, no statistically significant increase of the incidence of adverse effects was found. However, further randomized studies with higher sample size and greater validity are needed to determine if TTM is worth implementing in CS patients.PMID:36200546 | DOI:10.5603/CJ.a2022.0093
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Adam Nieborek Jerzy R Ladny Milosz J Jaguszewski Andrea Denegri Aleksandra Sikora Szymon Pucylo Aleksandra Gasecka Michal Pruc Ivan Savytsky Lukasz Szarpak Source Type: research
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
CONCLUSIONS: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding.PMID:36200548 | DOI:10.5603/CJ.a2022.0091
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Manuel Anguita S ánchez Francisco Mar ín Jaime Masjuan Juan Cos ín-Sales Jos é Manuel Vázquez Rodríguez Vivencio Barrios Gonzalo Bar ón-Esquivias I ñaki Lekuona Alejandro I P érez-Cabeza Rom án Freixa-Pamias Francisco Javier Parra Jimenez Mohame Source Type: research
Should targeted temperature management be used in cardiogenic shock patients? Systematic review and meta-analysis
CONCLUSIONS: The present analysis shows no significant benefit of TTM in patients with CS. Moreover, no statistically significant increase of the incidence of adverse effects was found. However, further randomized studies with higher sample size and greater validity are needed to determine if TTM is worth implementing in CS patients.PMID:36200546 | DOI:10.5603/CJ.a2022.0093
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Adam Nieborek Jerzy R Ladny Milosz J Jaguszewski Andrea Denegri Aleksandra Sikora Szymon Pucylo Aleksandra Gasecka Michal Pruc Ivan Savytsky Lukasz Szarpak Source Type: research
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
CONCLUSIONS: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding.PMID:36200548 | DOI:10.5603/CJ.a2022.0091
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Manuel Anguita S ánchez Francisco Mar ín Jaime Masjuan Juan Cos ín-Sales Jos é Manuel Vázquez Rodríguez Vivencio Barrios Gonzalo Bar ón-Esquivias I ñaki Lekuona Alejandro I P érez-Cabeza Rom án Freixa-Pamias Francisco Javier Parra Jimenez Mohame Source Type: research
Should targeted temperature management be used in cardiogenic shock patients? Systematic review and meta-analysis
CONCLUSIONS: The present analysis shows no significant benefit of TTM in patients with CS. Moreover, no statistically significant increase of the incidence of adverse effects was found. However, further randomized studies with higher sample size and greater validity are needed to determine if TTM is worth implementing in CS patients.PMID:36200546 | DOI:10.5603/CJ.a2022.0093
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Adam Nieborek Jerzy R Ladny Milosz J Jaguszewski Andrea Denegri Aleksandra Sikora Szymon Pucylo Aleksandra Gasecka Michal Pruc Ivan Savytsky Lukasz Szarpak Source Type: research
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
CONCLUSIONS: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding.PMID:36200548 | DOI:10.5603/CJ.a2022.0091
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Manuel Anguita S ánchez Francisco Mar ín Jaime Masjuan Juan Cos ín-Sales Jos é Manuel Vázquez Rodríguez Vivencio Barrios Gonzalo Bar ón-Esquivias I ñaki Lekuona Alejandro I P érez-Cabeza Rom án Freixa-Pamias Francisco Javier Parra Jimenez Mohame Source Type: research
Should targeted temperature management be used in cardiogenic shock patients? Systematic review and meta-analysis
CONCLUSIONS: The present analysis shows no significant benefit of TTM in patients with CS. Moreover, no statistically significant increase of the incidence of adverse effects was found. However, further randomized studies with higher sample size and greater validity are needed to determine if TTM is worth implementing in CS patients.PMID:36200546 | DOI:10.5603/CJ.a2022.0093
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Adam Nieborek Jerzy R Ladny Milosz J Jaguszewski Andrea Denegri Aleksandra Sikora Szymon Pucylo Aleksandra Gasecka Michal Pruc Ivan Savytsky Lukasz Szarpak Source Type: research
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
CONCLUSIONS: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding.PMID:36200548 | DOI:10.5603/CJ.a2022.0091
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Manuel Anguita S ánchez Francisco Mar ín Jaime Masjuan Juan Cos ín-Sales Jos é Manuel Vázquez Rodríguez Vivencio Barrios Gonzalo Bar ón-Esquivias I ñaki Lekuona Alejandro I P érez-Cabeza Rom án Freixa-Pamias Francisco Javier Parra Jimenez Mohame Source Type: research
Should targeted temperature management be used in cardiogenic shock patients? Systematic review and meta-analysis
CONCLUSIONS: The present analysis shows no significant benefit of TTM in patients with CS. Moreover, no statistically significant increase of the incidence of adverse effects was found. However, further randomized studies with higher sample size and greater validity are needed to determine if TTM is worth implementing in CS patients.PMID:36200546 | DOI:10.5603/CJ.a2022.0093
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Adam Nieborek Jerzy R Ladny Milosz J Jaguszewski Andrea Denegri Aleksandra Sikora Szymon Pucylo Aleksandra Gasecka Michal Pruc Ivan Savytsky Lukasz Szarpak Source Type: research
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
CONCLUSIONS: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding.PMID:36200548 | DOI:10.5603/CJ.a2022.0091
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Manuel Anguita S ánchez Francisco Mar ín Jaime Masjuan Juan Cos ín-Sales Jos é Manuel Vázquez Rodríguez Vivencio Barrios Gonzalo Bar ón-Esquivias I ñaki Lekuona Alejandro I P érez-Cabeza Rom án Freixa-Pamias Francisco Javier Parra Jimenez Mohame Source Type: research
